Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
For information on these and other studies, referring physicians may e-mail protocolinfo@stjude.org or call toll free physician referral line, 1-888-226-4343. If you are not a physician, please e-mail info@stjude.org for information on St. Jude studies.
Phase I Study of Bevacizumab and Sorafenib Combined with Low Dose Cyclophosphamide in Patients with Refractory Solid Tumors and Leukemia
For: Recurrent or refractory solid tumors and leukemias
A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) with and without Natural Killer Cells to Chemotherapy in Children and Adolescents with Recurrent/Refractory Neuroblastoma
For: Recurrent / refractory neuroblastoma
International Pediatric Adrenocortical Tumor Registry Data Collection
For: adrenocortical carcinoma
A Phase II Study Of Intensity Modulated Radiation Therapy (IMRT) In High-Risk Abdominal Neuroblastoma
For: High risk abdominal neuroblastoma
A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children with Relapsed or Refractory Solid Tumors or Lymphomas
For: Relapsed or refractory solid tumors or lymphomas
Image Guided Radiotherapy for the Treatment of Musculoskeletal Tumors: A Phase II Prospective Evaluation of Radiation-related Treatment Effects
For: Ewing sarcoma; rhabdomyosarcoma; primitive neuroectodermal tumors (PNET) of the musculoskeletal system; soft tissue sarcomas; other bone sarcomas; chordoma
A Phase I trial of the humanized anti-GD2 antibody (hu12.18K322A) in children and adolescents with neuroblastoma, osteosarcoma and melanoma
For: Neuroblastoma, osteosarcoma and melanoma
Non St. Jude Protocols
A Phase I dose escalation study of REOLYSIN, a replication competent reovirus, in pediatric patients with relapsed or refractory solid tumors
For: Recurrent solid tumors
A Phase I Study Of The C-Met Inhibitor Tivantinib (ARQ 197, IND#112603) In Children With Relapsed or Refractory Solid Tumors (ADVL1111)
For: Relapsed or refractory solid tumors or brain tumors
A Phase I Study of AMG 386 (IND#114215), An Angiopoietin Neutralizing Peptibody, In Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors (ADVL1115)
For: Relapsed or refractory solid tumors, including CNS tumors
A Phase I Study of XL184 (Cabozantinib, IND# 116059) In Children and Adolescents with Recurrent or Refractory Solid Tumors, Including CNS Tumors (ADVL1211)
For: Recurrent or refractory solid tumors, including CNS tumors
A Phase I Dose Escalation Study of Seneca Valley Virus (NTX-010), a Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients with Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors with Neuroendocrine Features
For: Neuroblastoma, rhabdomyosarcoma, Wilms tumor, retinoblastoma, adrenocortical carcinoma and carcinoid tumor
A Phase I/II Study of PF-02341066, An Oral Small Molecule Inhibitor Of Anaplastic Lymphoma Kinase (ALK) And C-Met, In Children With Relapsed/Refractory Solid Tumors And Anaplastic Large Cell Lymphoma
For: Relapses/refractory solid tumors and anaplastic large cell lymphoma
A Phase II Study of MLN8237 (IND#102984), A Selective Aurora Kinase Inhibitor, In Children with Recurrent/Refractory Solid Tumors and Leukemias (ADVL0921)
For: recurrent or refractory solid tumors (including rhabdoid and malignant germ cell tumors of the CNS) and leukemias
A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
For: Non-metastatic Ewing sarcoma
A Phase 2 Study of Ipilimumab in Children and adolescents (12 to < 18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma
For: Previously treated or untreated, unresectable Stage III or Stage IV malignant melanoma
An Open-label, Multicenter, Single-arm, Phase I Dose-escalation with Efficacy Tail Extension study of R05185426 in Pediatric Patients with Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600
For: melanoma
Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy
For: Nasopharyngeal carcinoma
Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy
For: Adrenocortical tumors
Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor
For: Wilms tumor
Treatment for Patients with Bilateral, Multicentric, or Bilaterally- Predisposed Unilateral Wilms Tumor
For: Wilms tumor
A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma
For: Extra-occular retinoblastoma
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)
For: Rhabdomyosarcoma
A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab[IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC # 742460]) inCombination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma
For: Rhabdomyosarcoma
A Randomized Phase II Trial of Bevacizumab (Avastin) and Temsirolimus (Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma
For: Recurrent or refractory rhabdomyosarcoma
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung
For: recurrent osteosarcoma
